• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Peripheral Artery Disease: Molecular Mechanisms and Novel Therapies.

作者信息

Athavale Anand, Fukaya Eri, Leeper Nicholas J

机构信息

Division of Vascular Surgery, Stanford University School of Medicine, Palo Alto, CA.

出版信息

Arterioscler Thromb Vasc Biol. 2024 Jun;44(6):1165-1170. doi: 10.1161/ATVBAHA.124.320195. Epub 2024 May 22.

DOI:10.1161/ATVBAHA.124.320195
PMID:38776386
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11157452/
Abstract
摘要

相似文献

1
Peripheral Artery Disease: Molecular Mechanisms and Novel Therapies.外周动脉疾病：分子机制与新疗法
Arterioscler Thromb Vasc Biol. 2024 Jun;44(6):1165-1170. doi: 10.1161/ATVBAHA.124.320195. Epub 2024 May 22.
2
Pathophysiology of Intermittent Claudication in Peripheral Artery Disease.外周动脉疾病间歇性跛行的病理生理学
Circ J. 2017 Feb 24;81(3):281-289. doi: 10.1253/circj.CJ-16-1286. Epub 2017 Jan 26.
3
Characteristics and outcomes of patients with peripheral artery disease undergoing endovascular revascularization: A community hospital perspective.周围动脉疾病患者行血管腔内血运重建术的特征和结局：社区医院视角。
Vascular. 2021 Jun;29(3):372-379. doi: 10.1177/1708538120958858. Epub 2020 Sep 21.
4
Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication.采用PL-VEGF165治疗间歇性跛行的外周动脉疾病患者的5年随访研究结果。
Ther Adv Cardiovasc Dis. 2018 Sep;12(9):237-246. doi: 10.1177/1753944718786926. Epub 2018 Jul 11.
5
Characteristics, Antithrombotic Patterns, and Prognostic Outcomes in Claudication and Critical Limb-Threatening Ischemia Undergoing Endovascular Therapy.腔内治疗的跛行和严重肢体缺血的特征、抗栓模式和预后结果。
J Endovasc Ther. 2024 Aug;31(4):622-633. doi: 10.1177/15266028221134886. Epub 2022 Nov 23.
6
Medical Optimization of Patients with Symptomatic Peripheral Arterial Disease.症状性外周动脉疾病患者的医学优化。
Ann Vasc Surg. 2024 Oct;107:170-180. doi: 10.1016/j.avsg.2024.01.027. Epub 2024 Apr 4.
7
Altered coagulation profile in peripheral artery disease patients.外周动脉疾病患者凝血谱的改变。
Vascular. 2020 Aug;28(4):368-377. doi: 10.1177/1708538120915997. Epub 2020 Apr 6.
8
Three-Year Outcomes of Orbital Atherectomy for the Endovascular Treatment of Infrainguinal Claudication or Chronic Limb-Threatening Ischemia.用于血管腔内治疗股腘动脉闭塞症或慢性肢体威胁性缺血的眼眶斑块旋切术的三年疗效
J Endovasc Ther. 2020 Oct;27(5):714-725. doi: 10.1177/1526602820935611. Epub 2020 Jul 3.
9
Aorto-iliac peripheral artery disease.主髂动脉周围血管疾病。
Prog Cardiovasc Dis. 2021 Mar-Apr;65:9-14. doi: 10.1016/j.pcad.2021.02.010. Epub 2021 Feb 22.
10
Role of genetics in peripheral arterial disease outcomes; significance of limb-salvage quantitative locus-1 genes.遗传学在周围动脉疾病结局中的作用；肢体挽救定量基因座-1 基因的意义。
Exp Biol Med (Maywood). 2018 Jan;243(2):190-197. doi: 10.1177/1535370217743460. Epub 2017 Dec 3.

引用本文的文献

1
TCF7L2 as a target of peripheral artery disease in patients with type 2 diabetes: A 2-sample Mendelian randomization and bioinformatics study.TCF7L2作为2型糖尿病患者外周动脉疾病的一个靶点：一项双样本孟德尔随机化和生物信息学研究。
Medicine (Baltimore). 2025 Feb 14;104(7):e41431. doi: 10.1097/MD.0000000000041431.
2
Role of C-Reactive Protein as a Predictor of Early Revascularization and Mortality in Advanced Peripheral Arterial Disease.C反应蛋白在晚期外周动脉疾病早期血管重建和死亡率预测中的作用
J Clin Med. 2025 Jan 26;14(3):815. doi: 10.3390/jcm14030815.
3
Benefits of Cilostazol's Effect on Vascular and Neuropathic Complications Caused by Diabetes.

本文引用的文献

1
Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors.用于心房颤动的抗凝剂：从华法林和直接口服抗凝剂到因子XI抑制剂的前景
Front Cardiovasc Med. 2024 Feb 5;11:1352734. doi: 10.3389/fcvm.2024.1352734. eCollection 2024.
2
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?ANGPTL3 和 ApoC-III 抑制剂治疗高甘油三酯血症：因马而异？
Curr Opin Lipidol. 2024 Jun 1;35(3):101-109. doi: 10.1097/MOL.0000000000000920. Epub 2024 Feb 19.
3
Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events.
西洛他唑对糖尿病引起的血管和神经并发症的疗效益处。
Med Sci (Basel). 2024 Dec 24;13(1):1. doi: 10.3390/medsci13010001.
4
Exploring research trends and hotspots on PCSK9 inhibitor studies: a bibliometric and visual analysis spanning 2007 to 2023.探索前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂研究的研究趋势和热点：一项涵盖2007年至2023年的文献计量学与可视化分析
Front Cardiovasc Med. 2024 Nov 22;11:1474472. doi: 10.3389/fcvm.2024.1474472. eCollection 2024.
脂蛋白(a)与外周动脉疾病、腹主动脉瘤和主要肢体不良事件的风险。
J Am Coll Cardiol. 2023 Dec 12;82(24):2265-2276. doi: 10.1016/j.jacc.2023.10.009.
4
Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.司美格鲁肽在射血分数轻度降低或保留的肥胖和心力衰竭患者中的应用。
J Am Coll Cardiol. 2023 Nov 28;82(22):2087-2096. doi: 10.1016/j.jacc.2023.09.811. Epub 2023 Oct 8.
5
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
6
Health Disparities in Peripheral Artery Disease: A Scientific Statement From the American Heart Association.外周动脉疾病中的健康差异：美国心脏协会的科学声明。
Circulation. 2023 Jul 18;148(3):286-296. doi: 10.1161/CIR.0000000000001153. Epub 2023 Jun 15.
7
Diabetes mellitus in peripheral artery disease: Beyond a risk factor.外周动脉疾病中的糖尿病：不仅仅是一个风险因素。
Front Cardiovasc Med. 2023 Apr 17;10:1148040. doi: 10.3389/fcvm.2023.1148040. eCollection 2023.
8
NLRP3 Inflammasome Activation in Peripheral Arterial Disease.NLRP3 炎性小体在周围动脉疾病中的激活作用。
J Am Heart Assoc. 2023 Mar 21;12(6):e026945. doi: 10.1161/JAHA.122.026945. Epub 2023 Mar 9.
9
Clonal Hematopoiesis Mutations Are Present in Atherosclerotic Lesions in Peripheral Artery Disease.动脉粥样硬化性疾病外周动脉病变中存在克隆性造血基因突变。
Int J Mol Sci. 2023 Feb 16;24(4):3962. doi: 10.3390/ijms24043962.
10
Medial artery calcification in peripheral artery disease.外周动脉疾病中的内侧动脉钙化
Front Cardiovasc Med. 2023 Jan 26;10:1093355. doi: 10.3389/fcvm.2023.1093355. eCollection 2023.